Obesity: Effects on the liver and gastrointestinal system

Current Opinion in Gastroenterology

Volumn 15, Issue 2, 1999, Pages 154-158

  Halsted, Charles H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; URSODEOXYCHOLIC ACID;

BODY MASS; CANCER RISK; CLINICAL TRIAL; COLON CANCER; COMORBIDITY; EPIDEMIC; FATTY LIVER; GALLSTONE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; GENERAL ASPECTS OF DISEASE; HEPATITIS; HUMAN; LIFESPAN; LIVER; LIVER DISEASE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; OBESITY; PATHOGENESIS; REVIEW; THERAPY; UNITED STATES;

EID: 0033006473     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199903000-00012     Document Type: Review

References (41)

1. 1 Halsted CH, Newton J, Phinney SD: Obesity and its health risks, Curr Opin Gastroenterol 1996, 12:204-209.
2. 2 Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr 1998, 68:899-917 Definitive and practical National Institutes of Health panel guidelines are presented on the definition of overweight and obesity and their clinical consequences.
3. 3 Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997, 1126:137-145. Comprehensive summary of NASH, including clinical and histopathological features and discussion of potential etiologies.
4. 4 Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
5. 5 Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ: Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22:222-226. This article demonstrates that hepatic steatosis improves, whereas inflammation may worsen after weight reduction surgory in severely obese patients.
6. 6 Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, et al: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996, 23:1464-1467.
7. 7 Day CO, James OFW: Steatohepatitis: a tale of two "hits." Gastroenterology 1998, 114:842-845. This provocative editorial proposes a working mechanism for the pathogenesis of NASH based on the oxidant properties of intrahepatic fatty acids.
8. 8 Letteron P, Fromenty B, Terris B, Degott C, Pessayre D: Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996, 24:200-208.
9. 9 Berson A, do Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, et al: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998, 114:764-774.
10. 10 Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM: Obesity increases sensitivity to endotoxin liver injury: implication for the pathogenesis of steatohepatitis. Proc Soc Acad Sci U S A 1997, 94:2557-2562.
11. 11 Flier JS, Maratos-Flier E: Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998, 92:437-440. This is a current comprehensive review of the physiology of leptin and newly described hypothalamic neuropeptides that regulate food intake, weight gain, and weight loss.
12. 12 Kaplan LM: Leptin, obesity, and liver disease. Gastroenterology 1998, 115:997-1001. This article provides a provocative summary of current knowledge on the roles of leptin and insulin in the development of NASH.
13. 13 Loffreda S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, et al: Leptin regulates proinflammatory immune responses. FASEB J 1998, 12:57-65, This study demonstrates that leptin enhances the synthesis of proinflammatory cytokines, significant in the context of NASH pathogenesis.
14. 14 Potter JJ, Womack L, Mezey E, Anania F: Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998, 244:178-182. This article reports an important discovery that hepatic stellate (fat-storing) cells are capable of producing leptin.
15. 15 McCullough AJ, Buglianesi E, Marchesini G, Kalhan SC: Gender-depen-dent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology 1998, 115:947-953. Leptin may play a role in induction of malnutrition in alcoholic fiver disease.
16. 16 Stampfer MJ, Maclure KM, Colditz GA, Manson JE, Willett WC: Risk of symptomatic gallstones in women with severe obesity. Am J Clin Nutr 1992, 55:652-658.
17. 17 Shiftman ML, Sugerman HJ, Kellum JH, Brewer WH, Moore EW: Gallstones in patients with morbid obesity: relationship to body weight, weight loss and gallbladder bile cholesterol solubility. Int J Obes Relat Metab Disord 1993, 17:153-158.
18. 18 Hendel HW, Hojgaard L, Andersen T, Pedersen BH, Paloheimo LI, Rehfeld JF, et al: Fasting gallbladder volume and lithogenicity in relation to glucose tolerance, total and intraabdominal fat masses in obese non-diabetic subjects. Int J Obes Relat Metab Disord 1998, 22:284-302. This study of 57 obese Danish patients showed that bile cholesterol saturation increases according to total body fat (an index of BMI), whereas intra-abdominal fat is a determinant of gallbladder volume.
19. 19 Stone BG, Ansel HJ, Peterson FJ, Gebhard RL: Gallbladder emptying stimuli in obese and normal-weight subjects. Hepatology 1992, 15:795-798.
20. 20 Weinsier RL, Wilson LJ, Lee J: Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation. Am J Med 1995, 98:115-117.
21. 21 Heshka S, Spitz A, Nunez C, Fittante AM, Heymsfield SB, Pi-Sunyer FX: Obesity and risk of gallstone development on a 1200 kcal/d (5025 Kj/d) regular food diet. Int J Obes Relat Metab Disord 1996, 20:450-454.
22. 22 Vezina WC, Grace M, Hutton LC, Alfieri MH, Colby PR, Downey DB, et al: Similarity in gallstone formation from 900 kcal/day diets containing 16 g vs 30 g of daily fat. Dig Dis Sci 1998, 43:554-561. Reducing calories to 900 kcal/d but not fat resulted in significant weight loss but greater than 10% incidence of gallstones.
23. 23 Festi D, Colecchia A, Orsini M, Sangermano A, Sottilli S, Simoni P, et al: Gallbladder motility and gallstone formation in obese patients following very low calorie diets: use it (fat) to lose it (well). Int J Obes Relat Metab Disord 1998, 22:592-600. Modest inclusion of dietary fat is protective against gallstone formation when using very-low-calorie diets (<600 kcal/d) in severely obese patients.
24. 24 Sugerman HJ, Brewer WH, Shiftman ML, Brolin RE, Fobi MA, Linner JH, et al: A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss Am J Surg 1995, 169:91-96.
25. 25 Shiftman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF: Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995, 122:899-905.
26. 26 Shoheiber O, Biskupiak JE, Nash DB: Estimation of the cost savings resulting from the use of ursodiol For the prevention of gallstones in obese patients undergoing rapid weight reduction. Int J Obes Relat Metab Disord 1997, 21:1038-1045. Documentation of the cost effectiveness of ursodiol in the prevention of new gallstones during weight loss based on the above two clinical trials.
27. 27 Romero Y, Cameron AJ, Locke GR, Schaid DJ, Slezak JM, Branch CD, Melton LJ: Familial aggregation of gastroesophageal reflux in patients with Barren's esophagus and esophageal adenocarcinoma, Gastroenterology 1997, 113:1449-1456. Obesity is a significant determinant of GERD among relatives of patients with Barrett esophagus and adenocarcinoma of the esophagus,
28. 28 Williamson WA, Ellis FH Jr, Gibb SP, Shahian DM, Aretz HT, Heatley GJ, Watkins E: Barrett's esophagus: prevalence and incidence of adenocarcinoma. Arch Intern Med 1991, 151:2212-2216.
29. 29 Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS, et al: Adenocarcinoma of the esophagus: Role of obesity and diet. J Natl Cancer Inst 1995, 87:104-109.
30. 30 Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP Jr, Edwards SM: Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord 1998, 22:178-184. A case-control study of 1983 patients with colon cancer demonstrates significantly greater odds ratio for development of colon cancer with increasing BMI.
31. 31 Giovannucci E, Goldin B: The role of fat, fatty acids, and total energy intake in the etiology of human colon cancer. Am J Clin Nutr 1997, 66:1564S-1571S. Extensive review providing evidence for the predominant roles of high saturated beef fat and increased energy intake in the risk of developing colonie adenoma and cancer.
32. 32 Consensus Development Conference Panel: Gastrointestinal surgery for severe obesity: consensus development conference statement. Ann Intern Med 1991, 115:956-961.
33. 33 Scopinaro N, Gianetta E, Adami GF: Biliopancreatic diversion for obesity at eighteen years. Surgery 1996, 119:261-268.
34. 34 Noya G, Cossu ML, Coppola M, Tonolo G, Anglus MF, Fais E, Rugglu M: Biliopancreatic diversion for treatment of morbid obesity: experience in 50 cases. Obes Surg 1998, 8:61-66.
35. 35 Baltasar A, Bou R, Arlandis F, Martinez R, Serra C, Bengochea M, Miro J: Vertical banded gastroplasty at more than 5 years. Obes Surg 1998, 8:29-34. This article documents unacceptable complications after vertical banded gastroplasty.
36. 36 Ovrebo KK, Hatlebakk JG, Viste A, Abssoe HH, Svanes K: Gastroesophageal reflux in morbidly obese patients treated with gastric banding or vertical banded gastroplasty, Ann Surg 1998, 228:51-58. Frequent esophageal reflux follows gastric banding and vertical banded gastroplasty.
37. 37 Jones KKB: Roux-en-Y gastric bypass: an effective antireflux procedure in the less than morbidly obese, Obes Surg 1998, 8:35-38. GB is beneficial in treating esophageal reflux in obese patients over a wide BMI range.
38. 38 Kirkpatrick JR, Zapas JL: Divided gastric bypass: a fifteen year experience. Am Surgeon 1998, 64:62-65. Positive results from GB lead to enthusiastic endorsement of this surgical refinement of division of the stomach.
39. 39 Rhode BM, Arseneau P, Cooper BA, Katz M, Gilfix BM, MacLean LD: Vitamin B-1 2 deficiency after gastric surgery for obesity. Am J Clin Nutr 1996,63:103-109.
40. 40 Atchison M, Wade T, Higgins B, Slavotinek T: Anorexia nervosa following gastric reduction surgery for morbid obesity. Int J Eat Disord 1998, 23:11-116.
41. 41 van Gemert WG, Severeijns RM, Greve JWM, Groenman N, Soeters PB: Psychological functioning of morbidly obese patients after surgical treatment. Int J Obes Relat Metab Disord 1998, 22:393-398. This article documents improved well-being among patients who lose weight with obesity surgery.